An Open-label Study of Excretion Balance and Pharmacokinetics Following a Single Oral Dose of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Sodium valproate (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Sanofi
- 22 Jan 2019 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.
- 22 Jan 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Feb 2019.
- 19 Dec 2018 Status changed from recruiting to active, no longer recruiting.